Neuronetics to Participate at B. Riley Securities’ Mind, Muscle & Vision Summit

Neuronetics will participate in B. Riley's Mind, Muscle & Vision Summit, discussing neuropsychiatric drug commercialization on July 16, 2026.

Quiver AI Summary

Neuronetics, Inc. announced its participation at the B. Riley Securities' Mind, Muscle & Vision Summit, taking place on July 16, 2026, in Boston. The company will engage in a panel discussion on "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," along with Compass Pathways. Neuronetics, known for its NeuroStar® TMS technology and extensive network of interventional psychiatry clinics through Greenbrook, focuses on innovative treatments for mental health conditions, particularly major depressive disorder (MDD). The NeuroStar Advanced Therapy system is a leading, FDA-cleared non-drug treatment for MDD and is supported by substantial clinical data. Neuronetics emphasizes the significance of its treatments in offering alternatives for patients who have not responded to traditional medications.

Potential Positives

Neuronetics' participation in the B. Riley Securities' Mind, Muscle & Vision Summit positions the company as a key player in the interventional mental health space, enhancing visibility among institutional investors.
Engagements like the panel discussion on "Commercializing the Next Wave of Novel Neuropsychiatric Drugs" demonstrate Neuronetics' commitment to innovation and leadership in mental health treatment solutions.
The presence of company management for one-on-one meetings with institutional investors may strengthen relationships and open avenues for future investment opportunities.

Potential Negatives

The press release does not provide any financial updates or projections, which may raise concerns about the company’s current performance and future outlook among investors.
The absence of a live webcast for the upcoming panel discussion limits accessibility for interested stakeholders and may indicate a lack of transparency.
The disclaimer regarding the effectiveness of SPRAVATO® in preventing suicide may cast doubts on the overall efficacy of their offerings in a sensitive market.

FAQ

What event is Neuronetics participating in?

Neuronetics will participate in the B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026.

What will the panel discussion focus on?

The panel discussion will focus on "Commercializing the Next Wave of Novel Neuropsychiatric Drugs."

Is the event open to the public?

No, it is an invitation-only event with no live webcast available.

What technologies does Neuronetics specialize in?

Neuronetics specializes in interventional mental health, particularly with its NeuroStar® TMS technology and SPRAVATO® treatments.

Where are Greenbrook treatment centers located?

Greenbrook operates one of the largest interventional psychiatry clinic networks in the United States.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

EARLY ACCESS

Receive STIM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$STIM Insider Trading Activity

$STIM insiders have traded $STIM stock on the open market 20 times in the past 6 months. Of those trades, 12 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:

JOREY CHERNETT has made 12 purchases buying 3,568,314 shares for an estimated $4,703,708 and 0 sales.
KEITH J SULLIVAN has made 0 purchases and 3 sales selling 121,112 shares for an estimated $181,387.
WILLIAM ANDREW MACAN (EVP, CLO and CS) has made 0 purchases and 4 sales selling 34,219 shares for an estimated $50,962.
STEVEN PFANSTIEL (EVP, CFO and Treasurer) sold 16,431 shares for an estimated $22,017

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$STIM Revenue

$STIM had revenues of $34.5M in Q1 2026. This is an increase of 7.75% from the same period in the prior year.

You can track STIM financials on Quiver Quantitative's STIM stock page.

You can access data on STIM stock through the Quiver Quantitative API.

$STIM Hedge Fund Activity

We have seen 42 institutional investors add shares of $STIM stock to their portfolio, and 41 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANE STREET GROUP, LLC removed 1,001,288 shares (-98.4%) from their portfolio in Q1 2026, for an estimated $1,451,867
RENAISSANCE TECHNOLOGIES LLC removed 474,900 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $688,605
ADVISORSHARES INVESTMENTS LLC added 346,277 shares (+127.8%) to their portfolio in Q1 2026, for an estimated $502,101
MARSHALL WACE, LLP removed 286,045 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $414,765
UBS GROUP AG added 263,551 shares (+10.1%) to their portfolio in Q1 2026, for an estimated $382,148
STATE STREET CORP added 258,380 shares (+44.2%) to their portfolio in Q1 2026, for an estimated $374,651
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 235,080 shares (-73.1%) from their portfolio in Q1 2026, for an estimated $340,866

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Full Release

MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.

Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.

This is an in-person, invitation-only event, and there will be no live webcast of the panel discussion.

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com .

Investor Contact:

Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]

Media Contact:

EvolveMKD
646-517-4220
[email protected]

References
¹ The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com .